Resistencia antimicrobiana de pseudomonas aeruginosa aislada en pacientes de la Clínica D.A.M.E. en el periodo agosto 2013-agosto 2014
No hay miniatura disponible
Fecha
2016
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Químicas
Resumen
Pseudomonas aeruginosa (P. aeruginosa) es una bacteria patógena, que posee evidencia clínica de prevalencia nosocomial y frecuentemente causa neumonía, infección de vías urinarias, infección de heridas y bacteriemia en pacientes que se encuentran hospitalizados. La infección por la bacteria P. aeruginosa está asociada directamente a una permanencia prolongada en hospitalización y sobre todo en la unidad de cuidados intensivos, incremento en la ventilación mecánica, en comparación con otros agentes bacterianos. La infección por diferentes cepas que son resistentes de esta bacteria se ha convertido en un aumento de la morbilidad, mortalidad y en el gasto del paciente por hospitalización. P. aeruginosa es un importante y frecuente patógeno causante de una amplia serie de infecciones, tanto comunitarias como de ámbito hospitalario. Debido al alto grado de resistencia intrínseca que presenta y su facilidad para adquirirla vía mutación, han aparecido cepas resistentes a la mayoría de los antimicrobianos con actividad antipseudomonal lo que plantea serios problemas terapéuticos. La bacteria mencionada posee múltiples sistemas de degradación enzimática específicos, principalmente productores de betalactamasas. La mayoría o relativamente todas especies de esta bacteria producen betalactamasas cromosomales, las mismas que tienen y poseen actividad de cefalosporinasa y son inducibles al exponerse a los antibióticos betalactámicos.
El presente estudio se desarrolló en el laboratorio de Microbiología de una clínica privada de la ciudad de Quito en donde se determinó el perfil de resistencia/sensibilidad de Pseudomonas aeruginosa aislada en los pacientes hospitalizados en el período Agosto
2013 – Agosto 2014, observando la resistencia a los antibióticos con los siguientes resultados: Colistina (CL) 0 %, Amikacina (AK) 35%, Meropenem (MEM) 57%, Imipenem (IMP) 59%, Piperacilina Tazobactam (TPZ) 47%, Ciprofloxacina (CIP) 21%, Cefepime (FEP) 50%, Ceftazidima (CAZ) 37.4 %, Aztreonam (ATM) 45%.
Pseudomonas aeruginosa (P. aeruginosa) is a pathogenic bacterium that has clinical evidence of nosocomial prevalence and frequently causes of pneumonia, urinary tract infection, wound infection and bacteremia in patients who are hospitalized. The infection by the bacterium P. aeruginosa is associated directly to a prolonged stay in hospital and especially in the intensive care unit, increased mechanical ventilation, compared with other bacterial agents. Infection with different strains that are resistant to this bacterium has become increased morbidity, mortality and patient spending for hospitalization. P. aeruginosa is an important and common pathogen causing a wide range of both Community and field hospital infections. Due to the high degree of intrinsic resistance presented and ease to acquire via mutation, they have appeared strains resistant to most antimicrobials antipseudomonal activity that poses serious therapeutic problems. The bacterium has multiple systems mentioned specific enzymatic degradation, mainly producing beta-lactamases. Most or relatively all species of this bacterium produce chromosomal beta-lactamase, they have and possess activity cephalosporinase and are inducible upon exposure to beta-lactam antibiotics. This study was realized in the laboratory of Microbiology at a private clinic in the city of Quito, where the profile of resistance / susceptibility of Pseudomonas aeruginosa isolated in hospitalized patients in the period August 2013 - in August 2014 was determined, noting the resistance antibiotics with the following results: colistin (CL) 0%, Amikacin (AK) 35%, Meropenem (MEM) 57%, imipenem (IMP) 59%, Piperacillin Tazobactam (TPZ) 47%, Ciprofloxacin (CIP) 21%, cefepime (FEP) 50%, ceftazidime (CAZ) 37.4% Aztreonam (ATM) 45%.
Pseudomonas aeruginosa (P. aeruginosa) is a pathogenic bacterium that has clinical evidence of nosocomial prevalence and frequently causes of pneumonia, urinary tract infection, wound infection and bacteremia in patients who are hospitalized. The infection by the bacterium P. aeruginosa is associated directly to a prolonged stay in hospital and especially in the intensive care unit, increased mechanical ventilation, compared with other bacterial agents. Infection with different strains that are resistant to this bacterium has become increased morbidity, mortality and patient spending for hospitalization. P. aeruginosa is an important and common pathogen causing a wide range of both Community and field hospital infections. Due to the high degree of intrinsic resistance presented and ease to acquire via mutation, they have appeared strains resistant to most antimicrobials antipseudomonal activity that poses serious therapeutic problems. The bacterium has multiple systems mentioned specific enzymatic degradation, mainly producing beta-lactamases. Most or relatively all species of this bacterium produce chromosomal beta-lactamase, they have and possess activity cephalosporinase and are inducible upon exposure to beta-lactam antibiotics. This study was realized in the laboratory of Microbiology at a private clinic in the city of Quito, where the profile of resistance / susceptibility of Pseudomonas aeruginosa isolated in hospitalized patients in the period August 2013 - in August 2014 was determined, noting the resistance antibiotics with the following results: colistin (CL) 0%, Amikacin (AK) 35%, Meropenem (MEM) 57%, imipenem (IMP) 59%, Piperacillin Tazobactam (TPZ) 47%, Ciprofloxacin (CIP) 21%, cefepime (FEP) 50%, ceftazidime (CAZ) 37.4% Aztreonam (ATM) 45%.
Descripción
pdf
Palabras clave
PSEUDOMONAS AEUROGINOSA, RESISTENCIA ANTIMICROBIANA, ANTIBIOTICOTERAPIA